Payment overview · 2025
General Payments
$382.22
15 reported records · 4 companies
Healthcare provider profile · identity verified
Luis J Suau, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · MAYAGUEZ, PR · NPI 1366418014
Verified facts
What the public records show
CMS Open Payments records show Luis J Suau, MD received $382.22 in general payments during 2025 across 15 reported records.
Janssen Pharmaceuticals, Inc accounted for 68.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Verzenio.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Imbruvica by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUPRON DEPOT as an associated drug or biological on 6475 records involving 3205 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lupron Depot by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Eli Lilly Export S.A. Puerto Rico Branch reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERZENIO as an associated drug or biological on 301 records involving 104 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Verzenio by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ERLEADA as an associated drug or biological on 790 records involving 308 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Erleada by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $263.15 | 68.8% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $54.94 | 14.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.56 | 8.5% | 2 | 2025 |
| Eli Lilly Export S.A. Puerto Rico Branch | Unresolved — no canonical attribution shown | $31.57 | 8.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $382.22 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DARZALEX Normalized: darzalex |
Biological | Janssen Pharmaceuticals, Inc | $263.15 | 10 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological | AstraZeneca Pharmaceuticals LP | $54.94 | 2 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $32.56 | 2 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $32.56 | 2 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $31.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VERZENIO verzenio |
2025 | Verzenio | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUPRON DEPOT open payments reported associated product |
CMS Open Payments — General Payments 6475 supporting records · 3205 recipient NPIs · example record 1201352804 |
Lupron Depot · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Eli Lilly Export S.A. Puerto Rico Branch Exact reporting entity; no affiliate inference |
2025 | VERZENIO open payments reported associated product |
CMS Open Payments — General Payments 301 supporting records · 104 recipient NPIs · example record 1186465135 |
Verzenio · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | ERLEADA open payments reported associated product |
CMS Open Payments — General Payments 790 supporting records · 308 recipient NPIs · example record 1174226359 |
Erleada · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Tamoxifen Citrate | Tamoxifen Citrate | 91 | 13 |
| Hydroxyurea | Hydroxyurea | 88 | suppressed |
| Bicalutamide | Bicalutamide | 47 | suppressed |
| Dexamethasone | Dexamethasone | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 30 | suppressed |
| Revlimid | Lenalidomide | 30 | suppressed |
| Trelstar | Triptorelin Pamoate | 27 | suppressed |
| Pomalyst | Pomalidomide | 26 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 22 | suppressed |
| Ninlaro | Ixazomib Citrate | 21 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 20 | suppressed |
| Xtandi | Enzalutamide | 20 | suppressed |
| Letrozole | Letrozole | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Imbruvica | Ibrutinib | 18 | suppressed |
| Lenalidomide | Lenalidomide | 18 | suppressed |
| Lupron Depot | Leuprolide Acetate | 17 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Erleada | Apalutamide | 14 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 14 | suppressed |
| Everolimus | Everolimus | 13 | suppressed |
| Verzenio | Abemaciclib | 13 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 12 | suppressed |
| Kisqali | Ribociclib Succinate | 12 | suppressed |
| Omeprazole | Omeprazole | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 11 | suppressed |
| Scemblix | Asciminib Hydrochloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $382.22 · 15 records | Janssen Pharmaceuticals, Inc | DARZALEX, ENHERTU, EPKINLY, VENCLEXTA, VERZENIO | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Verzenio play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error